LEARN ABOUT OUR PURPOSE & COMITTMENT TO IMPROVING PATIENT QUALITY OF LIFE Skye Biologics, a U.S.-based leader in biotechnology, was founded in 2006 to develop and manufacture Extracellular Matrix Biologic (BioECM) products designed to engage and assist the body in its natural ability to restore damaged connective tissues. Skye Biologics products have been used in over 200,000 tissue-repair treatments nationwide, to augment and support degenerated or damaged tissues in surgical repairs and non-operative therapy as a potential alternative to surgery.

Skye PX50: ptm common Sports medicine conditions One Joint 2,995 Two Joints 4,475 Three Joints 6,720 PX50™ & DX100™ are part of Skye’s BioRenew® PTM Therapy® product line, and are designed specifically for treating in-office non-operative conditions, sports medicine and interventional applications. PTM Therapy® products are derived from donated human placentas, and provide a complete, high- performance biologic solution to effectively support the body’s natural recovery process. SKYE DX100: PTM for Complex and Interventional Conditions ONE JOINT 3,885 TWO JOINT 5,485 THREE JOINTS 8,725

INVITRX THERAPEUTICS, headquartered in Orange County California is a global research-based biotechnology company with over 15 years of product development industry experience. Established in 2003, Invitrx has been a leading pioneer in Regenerative Stem Cell Medicine. Invitrx began as a developer of autologous tissue grafts for burn patients, which evolved organically into a global expansion of our cell therapy products.

Invitra Cord Blood Stem Cells and Whartons Jelly Invitrix Cord Blood Stem Cell and Whartons Jelly ONE JOINT 4,195 TWO JOINTS 6,885 THREE JOINTS 8,795 Invitra Cord Blood Stem Cells and Whartons Jelly Invitra WJ-C™ Structural Wharton’s Jelly Allograft Invitra WJ-C™ is a minimally manipulated human tissue allograft suspension derived from the Wharton’s Jelly of the umbilical cord. Invitrx Therapeutics utilizes a proprietary process to preserve the growth and other native components of the Wharton’s Jelly for homologous use.

InvitrIx Umbilical cord blood plasma (hUCBP) IV Therapy 5,500 *May be combined with most joint injections and will aid with chronic conditions Invitrx human umbilical cord blood plasma (hUCBP) is a minimally manipulated product derived from the liquid phase of blood and is rich IN VARIOUS CYTOKINESGROWTH FACTORS AND IMMUNE MODULATORY FACTORS. These messaging molecules are able to regulate immune and adult stem cells to promote homeostatsis. In addition, these growth factors and CYTOKINES CONTAIN PLASTICITY PROMOTING PROTEINS THAT MAY HAVE AGE managing effects. In addition, hUCBP has been shown to activate quiescent neural stem cells in the subventricular zone and modulate how T cells produce, which may assist or be involved in brain injury recovery. Invitrx hUCBP has been developed on over 15 years of research.

Invitra CBSC™ Invitra Cord Blood Stem Cells ONE JOINT 4,195 TWO JOINTS 6,885 THREE JOINTS 8,795 IV Therapy 5,500 May be Combined with most other joint therapies and will be recommended for chronic conditions Invitra CBSC™ Invitra Cord Blood Stem Cells Invitra Cord Blood Stem Cells (CBSC) is a minimally manipulated human tissue allograft suspension derived from umbilical cord blood. Invitrx Therapeutics utilizes a proprietary process to preserve the tissue characteristics and properties. . Cord blood contains a mixed population of cells, including hematopoietic stem cells (HSC) and mesenchymal stems cells (MSC). These cells have the capacity to self-renew, release growth factors, and further develop into more specialized cells. These cells have also been associated with contributing to tissue homeostasis, anti-inflammatory RESPONSES AND ANTIOXIDANT EFFECTS THIS COLLECTION OF CELLS CAN WORK together to provide a synergistic effect to offset the naturally occurring processes that typically derive from age and environmental factors. Quality Assurance Invitra CBSC™ is processed from donated umbilical cords from full term deliveries. All donors are Pre- screened and undergo comprehensive testing that includes: BEHAVIORAL RISK ASSESSMENT PHYSICAL ASSESSMENT DONOR MEDICAL HISTORY COMMUNICABLE DISEASE TESTING Infectious disease testing is performed at a certified laboratory in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR part 493